Association of genetic variation in pharmacodynamic factors with methadone dose required for effective treatment of opioid addiction

Pharmacogenomics

Volumn 14, Issue 7, 2013, Pages 755-768

  Levran, Orna ^a   Peles, Einat ^b   Randesi, Matthew ^a   Shu, Xu ^c   Ott, Jurg ^a,d   Shen, Pei Hong ^e   Adelson, Miriam ^b   Kreek, Mary Jeanne ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^c UNIVERSITY OF MICHIGAN   (United States)

^d INSTITUTE OF PSYCHOLOGY   (China)

^e NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

Author keywords

ANKK1; BDNF; DRD2; methadone maintenance; NTRK2; OPRM1; pharmacogenetics

Indexed keywords

ANKYRIN REPEAT AND KINASE DOMAIN CONTAINING 1; BETA ARRESTIN 2; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; DOPAMINE 2 RECEPTOR; GLUTAMATE RECEPTOR 1; GLUTAMATE RECEPTOR 2; GROWTH FACTOR RECEPTOR; METHADONE; MU OPIATE RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; NERVE GROWTH FACTOR BETA SUBUNIT; NEUROTROPHIC TYROSINE KINASE RECEPTOR TYPE 1; PROOPIOMELANOCORTIN; PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC VARIABILITY; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; OPIATE ADDICTION; PHARMACODYNAMICS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM;

FEMALE; GENE EXPRESSION; HUMANS; MALE; METHADONE; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84877674687     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.58     Document Type: Article

References (102)

1. Kreek MJ, Borg L, Ducat E, Ray B. Pharmacotherapy in the treatment of addiction: methadone. J. Addict. Dis. 29(2), 200-216 (2010).
2. Wang L, Mcleod HL, Weinshilboum RM. Genomics and drug response. N. Engl. J. Med. 364(12), 1144-1153 (2011).
3. Gorman AL, Elliott KJ, Inturrisi CE. The d-and l-isomers of methadone bind to the non-competitive site on the N-methyl-d-aspartate (NMDA) receptor in rat forebrain and spinal cord. Neurosci. Lett. 223(1), 5-8 (1997).
4. Fredheim OM, Moksnes K, Borchgrevink PC, Kaasa S, Dale O. Clinical pharmacology of methadone for pain. Acta Anaesthesiol. Scand. 52(7), 879-889 (2008).
5. Adelson M, Peles E, Bodner G, Kreek MJ. Correlation between high methadone doses and methadone serum levels in methadone maintenance treatment (MMT) patients. J. Addict. Dis. 26(1), 15-26 (2007).
6. Kreek MJ. Methadone-related opioid agonist pharmacotherapy for heroin addiction. History, recent molecular and neurochemical research and future in mainstream medicine. Ann. NY Acad. Sci. 909, 186-216 (2000).
7. Plomin R, Haworth CM, Davis OS. Common disorders are quantitative traits. Nat. Rev. Genet. 10(12), 872-878 (2009).
8. Bohn LM, Lefkowitz RJ, Gainetdinov RR, Peppel K, Caron MG, Lin FT. Enhanced morphine analgesia in mice lacking b-arrestin 2. Science 286(5449), 2495-2498 (1999).
9. Gainetdinov RR, Premont RT, Bohn LM, Lefkowitz RJ, Caron MG. Desensitization of G protein-coupled receptors and neuronal functions. Annu. Rev. Neurosci. 27, 107-144 (2004).
10. Shukla AK, Xiao K, Lefkowitz RJ. Emerging paradigms of b-arrestin-dependent seven transmembrane receptor signaling. Trends Biochem. Sci. 36(9), 457-469 (2011).
11. Sinha R. Stress and addiction: a dynamic interplay of genes, environment, and drug intake. Biol. Psychiatry 66(2), 100-101 (2009).
12. Le Merrer J, Becker JA, Befort K, Kieffer BL. Reward processing by the opioid system in the brain. Physiol. Rev. 89(4), 1379-1412 (2009).
13. Di Chiara G, Bassareo V, Fenu S, et al. Dopamine and drug addiction: the nucleus accumbens shell connection. Neuropharmacology 47(Suppl. 1), 227-241 (2004).
14. Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc. Natl Acad. Sci. USA 85(14), 5274-5278 (1988).
15. Hoenicka J, Quinones-Lombrana A, Espana-Serrano L, et al. The ANKK1 gene associated with addictions is expressed in astroglial cells and upregulated by apomorphine. Biol. Psychiatry 67(1), 3-11 (2010).
16. Garrido E, Palomo T, Ponce G, Garcia-Consuegra I, Jimenez-Arriero MA, Hoenicka J. The ANKK1 protein associated with addictions has nuclear and cytoplasmic localization and shows a differential response of Ala239Thr to apomorphine. Neurotox. Res. 20(1), 32-39 (2011).
17. Callahan RJ, Au JD, Paul M, Liu C, Yost CS. Functional inhibition by methadone of N-methyl-d-aspartate receptors expressed in Xenopus oocytes: stereospecific and subunit effects. Anesth. Analg. 98(3), 653-659 (2004).
18. Levran O, Londono D, O'Hara K, et al. Heroin addiction in African Americans: a hypothesis-driven association study. Genes Brain Behav. 8(5), 531-540 (2009).
19. Autry AE, Monteggia LM. Brain-derived neurotrophic factor and neuropsychiatric disorders. Pharmacol. Rev. 64(2), 238-258 (2012).
20. Cowansage KK, Ledoux JE, Monfils MH. Brain-derived neurotrophic factor: a dynamic gatekeeper of neural plasticity. Curr. Mol. Pharmacol. 3(1), 12-29 (2010).
21. Nestler EJ, Barrot M, Dileone RJ, Eisch AJ, Gold SJ, Monteggia LM. Neurobiology of depression. Neuron 34(1), 13-25 (2002).
22. Koo JW, Mazei-Robison MS, Chaudhury D, et al. BDNF is a negative modulator of morphine action. Science 338(6103), 124-128 (2012).
23. Levran O, Peles E, Hamon S, et al. Nerve growth factor b polypeptide (NGFB) genetic variability: association with the methadone dose required for effective maintenance treatment. Pharmacogenomics J. 12(4), 319-327 (2012).
24. de Cid R, Fonseca F, Gratacos M, et al. BDNF variability in opioid addicts and response to methadone treatment: preliminary findings. Genes Brain Behav. 7(5), 515-522 (2008).
25. Oneda B, Crettol S, Bochud M, et al. b-arrestin2 influences the response to methadone in opioid-dependent patients. Pharmacogenomics J. 11(4), 258-266 (2011).
26. Hung CC, Chiou MH, Huang BH, et al. Impact of genetic polymorphisms in ABCB1, CYP2B6, OPRM1, ANKK1 and DRD2 genes on methadone therapy in Han Chinese patients. Pharmacogenomics 12(11), 1525-1533 (2011).
27. Crettol S, Besson J, Croquette-Krokar M, et al. Association of dopamine and opioid receptor genetic polymorphisms with response to methadone maintenance treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry 32(7), 1722-1727 (2008).
28. Barratt DT, Coller JK, Somogyi AA. Association between the DRD2 A1 allele and response to methadone and buprenorphine maintenance treatments. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 141(4), 323-331 (2006).
29. Lawford BR, Young RM, Noble EP, et al. The D(2) dopamine receptor A(1) allele and opioid dependence: association with heroin use and response to methadone treatment. Am. J. Med. Genet. 96(5), 592-598 (2000).
30. Doehring A, Hentig N, Graff J, et al. Genetic variants altering dopamine D2 receptor expression or function modulate the risk of opiate addiction and the dosage requirements of methadone substitution. Pharmacogenet. Genomics 19(6), 407-414 (2009).
31. Levran O, O'Hara K, Peles E, et al. ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence. Hum. Mol. Genet. 17(14), 2219-2227 (2008).
32. Levran O, Peles E, Hamon S, Randesi M, Adelson M, Kreek MJ. CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction. Addict. Biol. doi:10.1111/j.1369-1600.2011.00349.x (2011) (Epub ahead of print).
33. Hodgkinson CA, Yuan Q, Xu K, et al. Addictions biology: haplotype-based analysis for 130 candidate genes on a single array. Alcohol Alcohol. 43(5), 505-515 (2008).
34. Levran O, Londono D, O'Hara K, et al. Genetic susceptibility to heroin addiction: a candidate gene association study. Genes Brain Behav. 7(7), 720-729 (2008).
35. Enoch MA, Shen PH, Xu K, Hodgkinson C, Goldman D. Using ancestry-informative markers to define populations and detect population stratification. J. Psychopharmacol. 20(4 Suppl.), 19-26 (2006).
36. Attar MA, Salem JC, Pursel HS, Santy LC. CNK3 and IPCEF1 produce a single protein that is required for HGF dependent Arf6 activation and migration. Exp. Cell Res. 318(3), 228-237 (2012).
37. Liu QR, Walther D, Drgon T, et al. Human brain derived neurotrophic factor (BDNF) genes, splicing patterns, and assessments of associations with substance abuse and Parkinson's disease. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 134B(1), 93-103 (2005).
38. Rozen S, Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. Methods Mol. Biol. 132, 365-386 (2000).
39. Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 81(3), 559-575 (2007).
40. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21(2), 263-265 (2005).
41. Ducci F, Roy A, Shen PH, et al. Association of substance use disorders with childhood trauma but not African genetic heritage in an African-American cohort. Am. J. Psychiatry 166(9), 1031-1040 (2009).
42. Hout MC, Papesh MH, Goldinger SD. Multidimensional scaling. Wiley Interdiscip. Rev. Cogn. Sci. 4(1), 93-103 (2013).
43. Metz CE. Basic principles of ROC analysis. Semin. Nucl. Med. 8(4), 283-298 (1978).
44. Chen Z, Simmons MS, Perry RT, Wiener HW, Harrell LE, Go RC. Genetic association of neurotrophic tyrosine kinase receptor type 2 (NTRK2) with Alzheimer's disease. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 147(3), 363-369 (2008).
45. Behar DM, Yunusbayev B, Metspalu M, et al. The genome-wide structure of the Jewish people. Nature 466(7303), 238-242 (2010).
46. Atzmon G, Hao L, Pe'er I, et al. Abraham's children in the genome era: major Jewish diaspora populations comprise distinct genetic clusters with shared Middle Eastern Ancestry. Am. J. Hum. Genet. 86(6), 850-859 (2010).
47. Tian C, Kosoy R, Nassir R, et al. European population genetic substructure: further definition of ancestry informative markers for distinguishing among diverse European ethnic groups. Mol. Med. 15(11-12), 371-383 (2009).
48. Modarresi F, Faghihi MA, Lopez-Toledano MA, et al. Inhibition of natural antisense transcripts in vivo results in gene-specific transcriptional upregulation. Nat. Biotechnol. 30(5), 453-459 (2012).
49. Okada T, Hashimoto R, Numakawa T, et al. A complex polymorphic region in the brain-derived neurotrophic factor (BDNF) gene confers susceptibility to bipolar disorder and affects transcriptional activity. Mol. Psychiatry 11(7), 695-703 (2006).
50. Soliman F, Glatt CE, Bath KG, et al. A genetic variant BDNF polymorphism alters extinction learning in both mouse and human. Science 327(5967), 863-866 (2010).
51. Egan MF, Kojima M, Callicott JH, et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 112(2), 257-269 (2003).
52. Su N, Zhang L, Fei F, et al. The brain-derived neurotrophic factor is associated with alcohol dependence-related depression and antidepressant response. Brain Res. 1415, 119-126 (2011).
53. Zhang K, Yang C, Xu Y, et al. Genetic association of the interaction between the BDNF and GSK3B genes and major depressive disorder in a Chinese population. J. Neural. Transm. 117(3), 393-401 (2010).
54. Cheng CY, Hong CJ, Yu YW, Chen TJ, Wu HC, Tsai SJ. Brain-derived neurotrophic factor (Val66Met) genetic polymorphism is associated with substance abuse in males. Brain Res. Mol. Brain Res. 140(1-2), 86-90 (2005).
55. Uhl GR, Liu QR, Walther D, Hess J, Naiman D. Polysubstance abuse-vulnerability genes: genome scans for association, using 1,004 subjects and 1,494 single-nucleotide polymorphisms. Am. J. Hum. Genet. 69(6), 1290-1300 (2001).
56. Liu L, Foroud T, Xuei X, et al. Evidence of association between brain-derived neurotrophic factor gene and bipolar disorder. Psychiatr. Genet. 18(6), 267-274 (2008).
57. Neves-Pereira M, Mundo E, Muglia P, King N, Macciardi F, Kennedy JL. The brain-derived neurotrophic factor gene confers susceptibility to bipolar disorder: evidence from a family-based association study. Am. J. Hum. Genet. 71(3), 651-655 (2002).
58. Sklar P, Gabriel SB, McInnis MG, et al. Family-based association study of 76 candidate genes in bipolar disorder: BDNF is a potential risk locus. Mol. Psychiatry 7(6), 579-593 (2002).
59. Meng X, Kou C, Shi J, Yu Y, Huang Y. Susceptibility genes, social environmental risk factors and their interactions in internalizing disorders among mainland Chinese undergraduates. J. Affect. Disord. 132(1-2), 254-259 (2011).
60. Pae CU, Chiesa A, Porcelli S, et al. Influence of BDNF variants on diagnosis and response to treatment in patients with major depression, bipolar disorder and schizophrenia. Neuropsychobiology 65(1), 1-11 (2012).
61. Xie B, Wang B, Suo P, et al. Genetic association between BDNF gene polymorphisms and phobic disorders: a case-control study among mainland Han Chinese. J. Affect. Disord. 132(1-2), 239-242 (2011).
62. Kocabas NA, Antonijevic I, Faghel C, et al. Brain-derived neurotrophic factor gene polymorphisms: influence on treatment response phenotypes of major depressive disorder. Int. Clin. Psychopharmacol. 26(1), 1-10 (2011).
63. Gratacos M, Soria V, Urretavizcaya M, et al. A brain-derived neurotrophic factor (BDNF) haplotype is associated with antidepressant treatment outcome in mood disorders. Pharmacogenomics J. 8(2), 101-112 (2008).
64. Real E, Gratacos M, Soria V, et al. A brain-derived neurotrophic factor haplotype is associated with therapeutic response in obsessive-compulsive disorder. Biol. Psychiatry 66(7), 674-680 (2009).
65. Mercader JM, Ribases M, Gratacos M, et al. Altered brain-derived neurotrophic factor blood levels and gene variability are associated with anorexia and bulimia. Genes Brain Behav. 6(8), 706-716 (2007).
66. Beuten J, Ma JZ, Payne TJ, et al. Significant association of BDNF haplotypes in European-American male smokers but not in European-American female or African-American smokers. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 139B(1), 73-80 (2005).
67. Petryshen TL, Sabeti PC, Aldinger KA, et al. Population genetic study of the brain-derived neurotrophic factor (BDNF) gene. Mol. Psychiatry 15(8), 810-815 (2010).
68. Beuten J, Ma JZ, Payne TJ, et al. Association of specific haplotypes of neurotrophic tyrosine kinase receptor 2 gene (NTRK2) with vulnerability to nicotine dependence in African-Americans and European-Americans. Biol. Psychiatry 61(1), 48-55 (2007).
69. Alonso P, Gratacos M, Menchon JM, et al. Extensive genotyping of the BDNF and NTRK2 genes define protective haplotypes against obsessive-compulsive disorder. Biol. Psychiatry 63(6), 619-628 (2008).
70. Perroud N, Aitchison KJ, Uher R, et al. Genetic predictors of increase in suicidal ideation during antidepressant treatment in the GENDEP project. Neuropsychopharmacology 34(12), 2517-2528 (2009).
71. Murphy TM, Ryan M, Foster T, et al. Risk and protective genetic variants in suicidal behaviour: association with SLC1A2, SLC1A3, 5-HTR1B and NTRK2 polymorphisms. Behav. Brain Funct. 7, 22 (2011).
72. Xu K, Anderson TR, Neyer KM, et al. Nucleotide sequence variation within the human tyrosine kinase B neurotrophin receptor gene: association with antisocial alcohol dependence. Pharmacogenomics J. 7(6), 368-379 (2007).
73. Correia CT, Coutinho AM, Sequeira AF, et al. Increased BDNF levels and NTRK2 gene association suggest a disruption of BDNF/TrkB signaling in autism. Genes Brain Behav. 9(7), 841-848 (2010).
74. Dong C, Wong ML, Licinio J. Sequence variations of ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1, CRHR1 and NTRK2: association with major depression and antidepressant response in Mexican-Americans. Mol. Psychiatry 14(12), 1105-1118 (2009).
75. Usiello A, Baik JH, Rouge-Pont F, et al. Distinct functions of the two isoforms of dopamine D2 receptors. Nature 408(6809), 199-203 (2000).
76. Bertolino A, Fazio L, Caforio G, et al. Functional variants of the dopamine receptor D2 gene modulate prefronto-striatal phenotypes in schizophrenia. Brain 132(Pt 2), 417-425 (2009).
77. Zhang Y, Bertolino A, Fazio L, et al. Polymorphisms in human dopamine D2 receptor gene affect gene expression, splicing, and neuronal activity during working memory. Proc. Natl Acad. Sci. USA 104(51), 20552-20557 (2007).
78. Moyer RA, Wang D, Papp AC, et al. Intronic polymorphisms affecting alternative splicing of human dopamine D2 receptor are associated with cocaine abuse. Neuropsychopharmacology 36(4), 753-762 (2011).
79. Neville MJ, Johnstone EC, Walton RT. Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1. Hum. Mutat. 23(6), 540-545 (2004).
80. Gelernter J, Yu Y, Weiss R, et al. Haplotype spanning TTC12 and ANKK1, flanked by the DRD2 and NCAM1 loci, is strongly associated to nicotine dependence in two distinct American populations. Hum. Mol. Genet. 15(24), 3498-3507 (2006).
81. Yang BZ, Kranzler HR, Zhao H, Gruen JR, Luo X, Gelernter J. Association of haplotypic variants in DRD2, ANKK1, TTC12 and NCAM1 to alcohol dependence in independent case-control and family samples. Hum. Mol. Genet. 16(23), 2844-2853 (2007).
82. Noble EP. The D2 dopamine receptor gene: a review of association studies in alcoholism. Behav. Genet. 23(2), 119-129 (1993).
83. Chen D, Liu F, Shang Q, Song X, Miao X, Wang Z. Association between polymorphisms of DRD2 and DRD4 and opioid dependence: evidence from the current studies. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 156B(6), 661-670 (2011).
84. New AS, Perez-Rodriguez MM, Ripoll L, et al. Exploratory association study of genetic variation in OPRM1 gene and interpersonal dysfunction in a personality disorder enriched sample. Neuropsychopharmacology 36, S324-S449 (2011).
85. Shabalina SA, Zaykin DV, Gris P, et al. Expansion of the human μ-opioid receptor gene architecture: novel functional variants. Hum. Mol. Genet. 18(6), 1037-1051 (2009).
86. Pasternak GW. Molecular insights into μ opioid pharmacology: from the clinic to the bench. Clin. J. Pain 26(Suppl. 10), S3-S9 (2010).
87. Pan L, Xu J, Yu R, Xu MM, Pan YX, Pasternak GW. Identification and characterization of six new alternatively spliced variants of the human μ opioid receptor gene, Oprm. Neuroscience 133(1), 209-220 (2005).
88. Kreek MJ, Bart G, Lilly C, Laforge KS, Nielsen DA. Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments. Pharmacol. Rev. 57(1), 1-26 (2005).
89. Bond C, LaForge KS, Tian M, et al. Single-nucleotide polymorphism in the human μ opioid receptor gene alters b-endorphin binding and activity: possible implications for opiate addiction. Proc. Natl Acad. Sci. USA 95(16), 9608-9613 (1998).
90. Mague SD, Blendy JA. OPRM1 SNP (A118G): involvement in disease development, treatment response, and animal models. Drug Alcohol Depend. 108(3), 172-182 (2010).
91. Levran O, Yuferov V, Kreek MJ. The genetics of the opioid system and specific drug addictions. Hum. Genet. 131(6), 823-842 (2012).
92. Barratt DT, Coller JK, Hallinan R, et al. ABCB1 haplotype and OPRM1 118A>G genotype interaction in methadone maintenance treatment pharmacogenetics. Pharmacogenomics Pers. Med. 5, 53-62 (2012).
93. McGough JJ, Faraone SV. Estimating the size of treatment effects: moving beyond p values. Psychiatry (Edgmont.) 6(10), 21-29 (2009).
94. Siegel B, Vukicevic J, Spitzer RL. Using signal detection methodology to revise DSM-III-R: re-analysis of the DSM-III-R national field trials for autistic disorder. J. Psychiatr. Res. 24(4), 293-311 (1990).
95. Faraone SV, Biederman J, Spencer T, et al. Efficacy of atomoxetine in adult attention-deficit/hyperactivity disorder: a drug-placebo response curve analysis. Behav. Brain Funct. 1, 16 (2005).
96. Lenzini PA, Grice GR, Milligan PE, et al. Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients. J. Thromb. Haemost. 6(10), 1655-1662 (2008).
97. Bruehl S, Apkarian AV, Ballantyne JC, et al. Personalized medicine and opioid analgesic prescribing for chronic pain: opportunities and challenges. J. Pain 14(2), 103-113 (2013).
98. United Nations Office on Drugs and Crime, World Drug Report, 2011. www.unodc.org/unodc/en/data-and-analysis/WDR-2011.html
99. PLINK. http://pngu.mgh.harvard.edu/purcell/plink
100. Sumstat. www.jurgott.org/linkage/sumstat.html
101. International HapMap Project. http://hapmap.ncbi.nlm.nih.gov
102. The ALlele FREquency Database. http://alfred.med.yale.edu